KRAS and colorectal carcinoma: Bommareddy et al. demonstrated that combination of MEK inhibitor enhances antitumor effect of oncolytic herpes simplex virus against KRAS-mutant murine CRC tumors via enhancement of cytopathic activity and antitumor immunity [38].